Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AD/PD 2022 | The potential of vaccination for neurodegenerative disease

Johanne Kaplan • 17 Mar 2022
AD/PD 2022
Alzheimer’s Disease Dementia Vaccines

Johanne Kaplan, PhD, ProMIS™ Neurosciences, Inc., Cambridge, MA, explains the potential of vaccines with regards to neurodegenerative diseases. Current treatments such as antibodies require frequent administration, whereas a vaccine would only need a relatively low number of administrations to offer long term benefits. With future progress in the field of biomarkers it may eventually be possible during routine blood work for a clinician to offer a preventive vaccine to patients based on biomarker indications of increased risk. This interview took place at the AD/PD™ 2022 Conference in Barcelona, Spain.

Disclosures

Employee of ProMIS™ Neurosciences, Inc.

More from Johanne Kaplan

The future of immunotherapeutic approaches for the treatment of neurodegenerative diseases
1:58
The future of immunotherapeutic approaches for the treatment of neurodegenerative diseases
Johanne Kaplan • 7 Apr 2025
Exploring a vaccine-based approach to targeting Aβ oligomers in Alzheimer’s disease
3:02
Exploring a vaccine-based approach to targeting Aβ oligomers in Alzheimer’s disease
Johanne Kaplan • 7 Apr 2025
Promising vaccine targets for alpha-synucleinopathies
1:41
Promising vaccine targets for alpha-synucleinopathies
Johanne Kaplan • 7 Apr 2025
The complexity of vaccine development for neurodegenerative diseases
2:33
The complexity of vaccine development for neurodegenerative diseases
Johanne Kaplan • 7 Apr 2025

Related Videos

A multimodal model to detect and stage Alzheimer's disease using MRI, acoustic signals, and genetics
10:28
A multimodal model to detect and stage Alzheimer's disease using MRI, acoustic signals, and genetics
Muhammad Umar Khan • 28 Aug 2026
Neuroprotective effects of aortic valve replacement: a propensity score-matched cohort study
3:25
Neuroprotective effects of aortic valve replacement: a propensity score-matched cohort study
Vikash Jaiswal • 26 Aug 2026
The Lewy Body Society's mission and impact
2:38
The Lewy Body Society's mission and impact
Jacqui Cannon • 5 Aug 2026
Neflamapimod receives ILAP designation in the UK for dementia with Lewy bodies
2:44
Neflamapimod receives ILAP designation in the UK for dementia with Lewy bodies
Jacqui Cannon • 5 Aug 2026

Choose your cookie settings

VJDementia uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJDementia is intended for healthcare professionals